I was going to say that we have PTX200 due to be wrapped up soon. But just remembered that it too has been extended with the cohort numbers being increased due to its success to date. Its highly likely though that we will receive another readout at some stage.
I dont want to be thinking wishfully, but there is every possibility that we do land a customer for at least CellPryme-M and once we do, the dominoes could start to fall. Partners for CellPryme-A and OmniCAR may take more convincing to sign on... I don't know about others, but if find it hard not to notice the elevation in our status since CellPryme was unveiled and since TFS and MD Anderson signed collabs with us.
Steve is not just presenting at the AusBiotech conference in Perth, but he is one of the panelists for two discussions. That to me, illustrates that he and PTX is garnering a bit of prowess.
